| Parameters | Range |
| $ \alpha_T $ | $ 10^{-4}-0.45 $ |
| $ \rho_T $ | $ 7 \cdot 10^{-3} - 29.7 $ |
| $ a $ | $ 1.4-27 $ |
| $ b $ | $ 1.4 \cdot 10^{-4} - 6 \cdot 10^2 $ |
| $ K $ | $ 10^{-2}-11 $ |
We consider a model of CAR-T therapy for glioblastoma, focusing on the influence of time needed for an immune reaction to be triggered. This results in a system of delay differential equations which we investigate, studying the main properties of the model, including the number of steady states and their stability depending on the delay magnitude. Numerical simulations illustrate analytical results. We interpret mathematical results and formulate biological insights.
| Citation: |
Figure 1. Illustration of the processes that tumor cells (red cells) and CAR-T cells (green cells) undergo according to Eqs. (1). The left panel: tumor cell can proliferate at a rate of $ \rho_T $ or die by interactions with CAR-T cells at a rate of $ \alpha_T $. The right panel: CAR-T cells can be stimulated to division when encountering tumor cell at a time $ t-\tau $ with a rate $ a $, can be inactivated by tumor cells at a rate $ b $, or can undergo natural death
Figure 2. Phase portraits for Eqs. (1) without delay and with the logistic tumor growth for parameter values as follows: (1) $ a \leqslant 1 $; (2) $ a > 1 $ and $ g_{\min}>0 $ and (2a) $ K<K_{cr} $ (no positive steady state), (2b) $ K = K_{cr} $ (one positive steady state); (2c) $ K>K_{cr} $ and the first positive steady state being unstable; (2d) $ K>K_{cr} $ and the first positive steady state being stable; (3) $ a > 1 $ and $ g_{\min}<0 $ (one positive steady state)
Figure 5. Solution of Eqs. (1) with $ T(t) = 2\exp(5t) $ for $ t \in [-\tau,0] $ and $ C(t) = 0 $ for $ t \in [-\tau,0) $ and $ C(0) = 10 $ (1) the steady state $ (\bar T, \bar C) $ with $ \bar T< T_{min} $ is a stable focus, $ \tau = 0.1 $ (2) the steady state $ (\bar T, \bar C) $ with $ \bar T< T_{min} $ is unstable focus, $ \tau = 0.3 $. Other parameters $ a = 3; b = 1; \alpha_T = 0.45; \rho_T = 5; K = 5 $
Table 1. Parameters of the model described by Eqs. (1) based on the values from [6]. Note that these are non-dimensional parameters.
| Parameters | Range |
| $ \alpha_T $ | $ 10^{-4}-0.45 $ |
| $ \rho_T $ | $ 7 \cdot 10^{-3} - 29.7 $ |
| $ a $ | $ 1.4-27 $ |
| $ b $ | $ 1.4 \cdot 10^{-4} - 6 \cdot 10^2 $ |
| $ K $ | $ 10^{-2}-11 $ |
| [1] |
I. Abdulrashid, A. Alsammani and X. Han, Stability analysis of a chemotherapy model with delays,, Discrete and Continuous Dynamical Systems-B, 24 (2019), 989-1005.
doi: 10.3934/dcdsb.2019002.
|
| [2] |
S. J. Bagley and D. M. O'Rourke, Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions,, Pharmacol. Ther., 205 (2020), 107419.
doi: 10.1016/j.pharmthera.2019.107419.
|
| [3] |
L. R. C. Barros, et al., CARTmath-a mathematical model of CAR-T immunotherapy in
preclinical studies of hematological cancers, Cancers, 13 (2021), 2941.
doi: 10.3390/cancers13122941.
|
| [4] |
N. Bielczyk, M. Bodnar and U. Foryś, Delay can stabilize: Love affairs dynamics,, Applied Mathematics and Computation, 219 (2012), 3923-3937.
doi: 10.1016/j.amc.2012.10.028.
|
| [5] |
M. Bodnar, Distributed delays in Hes1 gene expression model,, Discrete and Continuous Dynamical Systems-B, 24 (2019), 2125-2147.
doi: 10.3934/dcdsb.2019087.
|
| [6] |
M. Bodnar, et al., On the analysis of a mathematical model of CAR-T cell therapy for glioblastoma: Insights from a mathematical model, International Journal of Applied Mathematics and Computer Science, 33 (2023), 379-394.
|
| [7] |
M. Bodnar, et al., Dual CAR-T cell therapy for glioblastoma: Strategies to cure tumour diseases based on a mathematical model, Nonlinear Dynamics, 113 (2025), 1637-1666.
|
| [8] |
M. Bodnar and U. Foryś, Three types of simple DDE's describing tumor growth,, Journal of Biological Systems, 15 (2007), 453-471.
doi: 10.1142/S0218339007002313.
|
| [9] |
M. P. Brown, L. M. Ebert and T. Gargett, Clinical chimeric antigen receptor-T cell therapy: A new and promising treatment modality for glioblastoma, Clin. Transl. Immunol., 8 (2019), e1050.
|
| [10] |
M. Castellarini, et al., Driving CARs to the clinic for solid tumors, Gene. Ther., 25 (2018), 165-175.
doi: 10.1038/s41434-018-0007-x.
|
| [11] |
B. Ermentrout, Simulating, Analyzing, and Animating Dynamical Systems: A Guide to XPPAUT for Researchers and Students, Software Environ. Tools, 14, Society for Industrial and Applied Mathematics (SIAM), Philadelphia, PA, 2002.
|
| [12] |
U. Foryś and B. Zduniak, Two-stage model of carcinogenic mutations with the influence of delays,, Discrete and Continuous Dynamical Systems-B, 19 (2014), 2501-2519.
doi: 10.3934/dcdsb.2014.19.2501.
|
| [13] |
L. Han, C. He and Y. Kuang, Dynamics of a model of tumor-immune interaction with time delay and noise,, Discrete and Continuous Dynamical Systems-B, 13 (2020), 2347-2363.
doi: 10.3934/dcdss.2020140.
|
| [14] |
O. León-Triana, et al., CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models, Communications in Nonlinear Science and Numerical Simulation, 94 (2021), Paper No. 105570, 21 pp.
|
| [15] |
O. Lóon-Triana, et al., Dual-target CAR-Ts with on- and off-tumour activity may override immune suppression in solid cancers: A mathematical proof of concept, Cancers, 13 (2021), 703.
|
| [16] |
S. Ma and et al., Current progress in CAR-T cell therapy for solid tumors, Int. J. Biol. Sci., 15 (2019), 2548-2560.
doi: 10.7150/ijbs.34213.
|
| [17] |
M. Martinez and E. K. Moon, CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment,, Front. Immunol., 10 (2019), 128.
doi: 10.3389/fimmu.2019.00128.
|
| [18] |
D. Migliorini, P.-Y. Dietrich, R. Stupp, G. P. Linette, A. D. Posey and C. H. June, CAR T-cell therapies in glioblastoma: A first look,, Clin. Cancer Res., 24 (2018), 535-540.
doi: 10.1158/1078-0432.CCR-17-2871.
|
| [19] |
H. Smith, An Introduction to Delay Differential Equations with Applications to the Life Sciences, Texts Appl. Math., 57, Springer, New York, 2011.
|
| [20] |
A. M. Stein, et al., Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells, CPT Pharmacom & Syst Pharma, 8 (2019), 285-295.
|
| [21] |
R. C. Sterner and R. M. Sterner, CAR-T cell therapy: Current limitations and potential strategies, Blood Cancer Journal, 11 (2021), 69.
|
| [22] |
R. Stupp, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, New Eng. J. Med., 352 (2005), 987-996.
|
| [23] |
R. Stupp, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncology, 10 (2009), 459-466.
|
| [24] |
D. Sturm, et al., Paediatric and adult glioblastoma: Multiform (epi)genomic culprits emerge, Nat. Rev. Cancer, 14 (2014), 92-107.
doi: 10.1038/nrc3655.
|
| [25] |
S. Tanaka, et al., Diagnostic and therapeutic avenues for glioblastoma: No longer a dead end?, Nat. Rev. Clin. Oncol., 10 (2013), 14-26.
doi: 10.1038/nrclinonc.2012.204.
|
Illustration of the processes that tumor cells (red cells) and CAR-T cells (green cells) undergo according to Eqs. (1). The left panel: tumor cell can proliferate at a rate of
Phase portraits for Eqs. (1) without delay and with the logistic tumor growth for parameter values as follows: (1)
Numerical simulation of a homoclinic bifurcation for Eqs. (1) without delay and with the logistic tumor growth with
Solution of Eqs. (1) with
Solution of Eqs. (1) with